AMRN - Amarin Corporation plc
After hours:
| Previous close | 1.1900 |
| Open | 1.1900 |
| Bid | 1.2000 x 3100 |
| Ask | 1.2000 x 1300 |
| Day's range | 1.1600 - 1.2200 |
| 52-week range | 1.0400 - 2.2300 |
| Volume | |
| Avg. volume | 3,188,406 |
| Market cap | 485.148M |
| Beta (5Y monthly) | 1.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | 03 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.13 |
Motley FoolAmarin Plc (AMRN) Q1 2023 Earnings Call Transcript
Greetings and welcome to Amarin Corporation's conference call to discuss its first-quarter 2023 financial results and operational update. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided under federal securities law.
ZacksAmarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
ZacksBiotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Simply Wall St.Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ZacksAscendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?
Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Motley FoolWhy Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
U.S. stock markets are under heavy pressure today after two reports on job openings and factory orders came in weaker than expected. The key issue at play is a growing concern that the Federal Reserve's rate hiking campaign may spark a deep and long-lasting economic downturn later this year. Topping it all off, OPEC+'s decision to reign in oil supplies this May has stock investors worried that the central bank may have to keep raising rates to tamp down inflation.
ZacksAmarin's (AMRN) Q4 Earnings and Revenues Beat Estimates
Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.
- Zacks
Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales
Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.
- Simply Wall St.
Amarin Full Year 2022 Earnings: US$0.26 loss per share (vs US$0.02 profit in FY 2021)
Amarin ( NASDAQ:AMRN ) Full Year 2022 Results Key Financial Results Revenue: US$369.2m (down 37% from FY 2021). Net...
ZacksSarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.
- Motley Fool
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript
Welcome to Amarin Corporation's conference call to discuss its fourth quarter and full year 2022 financial results and operational updates. After prepared remarks, we will open the call to your questions.
ZacksPerrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales
Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.
- Business Wire
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
GREENWICH, Conn., February 28, 2023--Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
- Business Wire
Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives
GREENWICH, Conn., February 27, 2023--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
- Zacks
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4
Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.
ReutersHikma accuses Amarin of suppressing generic versions of heart pill
Generic drugmaker Hikma Pharmaceuticals USA Inc has sued Amarin Pharma Inc, accusing it of using illegal tactics to delay generic competition for its heart drug Vascepa. In a complaint filed Tuesday in Trenton, New Jersey federal court, Hikma claimed that Amarin "deliberately and meticulously locked up the supply" of the key ingredient needed to make generic Vascepa in order to maintain a monopoly. London-based Hikma eventually launched the first generic version of Vascepa in November 2020, but it said that Amarin's tactics delayed the launch by months, and initially prevented Hikma from supplying enough of its generic to compete meaningfully with the branded version.
- Business Wire
Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote "FOR" Change
GREENWICH, Conn., February 21, 2023--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
- Business Wire
Sarissa Capital Urges Amarin Shareholders to Vote "FOR" Necessary Change
GREENWICH, Conn., February 20, 2023--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
- Business Wire
Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders
GREENWICH, Conn., February 17, 2023--Sarissa Capital Management LP ("Sarissa") today issued a presentation detailing the dire need for change at Amarin Corporation plc (NASDAQ: AMRN) accessible at the link below:
- Business Wire
Sarissa Capital Blasts Amarin’s Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board
GREENWICH, Conn., February 16, 2023--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
- Business Wire
Sarissa Capital Uncovers That Amarin’s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So
GREENWICH, Conn., February 15, 2023--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
- Business Wire
Sarissa Capital Disappointed That Amarin Webcast Continues Board’s Defense of Poor Results and Lack of Accountability
GREENWICH, Conn., February 14, 2023--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
ZacksAmarin (AMRN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Amarin (AMRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
ZacksIs Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
Here is how Bionano Genomics, Inc. (BNGO) and Amarin (AMRN) have performed compared to their sector so far this year.
- Business Wire
Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards
GREENWICH, Conn., February 13, 2023--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
